Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technology, ToRPPIDO, relies on genetic engineering and evolutionary selection to synthesize and identify compounds which modulate protein-protein interactions. SyntheX was founded in 2016 and was incubated at the IndieBio accelerator in San Francisco.
Maria has obtained her PhD from the department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a member of iGEM and a research scientist at a structural genomics laboratory, where her work led to the determination of numerous structures and identification of several drug candidates.